Overview of Eflora

Eflora is a prescription-only medication designed for topical administration to the skin, with its identity defined by the single active ingredient Eflornithine Hydrochloride. It is classified pharmacologically as an Ornithine Decarboxylase (ODC) Inhibitor.

Property	Description
Active ingredient	Eflornithine Hydrochloride
Form	Cream (Topical semisolid preparation)
Pharmacological class	Ornithine Decarboxylase (ODC) Inhibitor
General purpose	Modulates rapid cell growth
Origin	Synthetic (Alpha Amino Acid Derivative)

What Type of Medicine is Eflornithine?

Eflornithine Hydrochloride is a synthetic chemical compound classified as an Alpha Amino Acid Derivative and a targeted enzyme inhibitor. This designation places it among agents that interfere with specific biological processes within cells. Its primary classification as an Ornithine Decarboxylase (ODC) Inhibitor reflects its mechanism of action, which involves blocking the function of the ODC enzyme. The compound is characterized by its selective inhibitory properties, which work by interfering with the building blocks required for rapid cellular multiplication.

Eflora: Composition and General Purpose

Eflora is formulated as a topical cream, which serves as a vehicle to deliver the single active ingredient directly to the skin surface for external use only. The cream base, an emulsion of oil and water components, ensures efficient and controlled application of the active substance, Eflornithine Hydrochloride. The general purpose of Eflora, stemming from its pharmacological activity, is to modulate or slow down the rate of cellular processes that require high levels of essential polyamines. The medicine is intended to act topically on the skin to produce a localized growth-reducing effect where it is applied.

How Eflornithine is Different (Core Mechanism Summary)

Eflornithine's function is rooted in the highly specific cytostatic principle of irreversible inhibition of the ODC enzyme. This unique mode of action, scientifically termed "suicide inhibition," means Eflornithine binds permanently to and disables the target enzyme. This specific mechanism disrupts the enzyme's ability to produce polyamines, the critical building blocks necessary for rapid cell division. This highly targeted approach provides a controlled, non-hormonal intervention, positioning Eflora distinctly from therapeutic agents with broader systemic effects.

Regulatory References

VANIQA (Eflornithine) Prescribing Information

What side effects are possible with Eflora?

Eflornithine Hydrochloride cream is associated with a profile of adverse reactions primarily related to the application site, as detailed in official government regulatory documents. The safety profile is characterized by events categorized by their frequency, based on clinical trial data.

Frequency-Classified Adverse Reactions

The majority of side effects fall under Skin and Subcutaneous Tissue Disorders.

Classification	Examples of Reactions
Very Common (ge 1/10)	Acne
Common (ge 1/100 to < 1/10)	Pseudofolliculitis Barbae, stinging skin, burning skin, pruritus (itching), erythema (redness), dry skin, skin irritation, rash, headache, dyspepsia
Uncommon (ge 1/1,000 to < 1/100)	Ingrown hair, facial edema, dermatitis, herpes simplex, nausea, dizziness

Safety Considerations and Restrictions

The cream is contraindicated in any individual with a known hypersensitivity or allergy to the active substance or any of the inactive ingredients within the formulation. Regulatory labeling notes that the cream should be discontinued if intolerance or a hypersensitivity reaction develops, which represents a clinically significant adverse event.

Safety data for certain populations is limited or restricted. The safety and effectiveness of the cream have not been established in children under 12 years of age. Furthermore, while systemic absorption is low, official labeling advises caution regarding use during pregnancy and lactation, and encourages effective contraception for women of childbearing potential. Applying the cream to abraded or broken skin may result in transient stinging or burning, as noted in official safety documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Eflornithine Hydrochloride cream indicates that overdose is not expected from the correct topical application, given the medicine’s minimal absorption through the skin. However, the regulatory focus primarily addresses the risk associated with accidental oral ingestion of the cream or the application of extremely high topical doses.

Documented Overdose Manifestations

If significant systemic exposure occurs, regulatory information references the potential for severe effects known from high-dose administration of eflornithine. These manifestations include seizures and serious hematological toxicities such as anemia, thrombocytopenia, and leukopenia. Other documented systemic effects include dizziness, headache, facial swelling, and stomach upset.

Mandated Emergency Action

Immediate medical help must be sought if the cream is accidentally swallowed. Official regulatory guidance mandates contacting emergency services or a Poison Control center immediately upon oral ingestion. Management is defined as symptomatic and supportive, and the patient should be monitored in a clinical setting. No specific antidote is known for Eflornithine overdose. Furthermore, safety and efficacy have not been established in populations with hepatic or renal impairment or in children under 12 years of age.

Therapeutic Uses of Eflora

What Eflora Treats: Main Uses and Benefits

Topical Eflornithine cream is commonly used to help with the management of unwanted facial hair growth in women. The medication is relevant for easing symptoms related to hair growth, typically addressing the lips, chin, and adjacent areas of the face. The therapeutic benefit contributes to easing the overall symptom burden for a condition often associated with discomfort and psychological strain.

Managing Excessive and Undesirable Facial Hair (Hirsutism)

The medication is commonly used to help with hirsutism, which is characterized by the presence of dark, coarse terminal hair in a male-like pattern on the face. By supporting the symptomatic management of hair density, this therapy is relevant for easing symptoms that create noticeable interference with daily comfort.

Easing the Burden of Frequent Hair Removal

Eflornithine cream may assist with managing the burden associated with rapid and recurrent hair regrowth. The therapeutic benefit is applied in addressing symptomatic intensity, which may help lessen the impact of frequent physical hair removal methods, helping to improve day-to-day comfort.

Support for Chronic and Persistent Patterns

The cream is considered relevant for the long-term, chronic management of persistent facial hair growth, including conditions characterized by periods of heightened symptoms, such as those associated with Polycystic Ovary Syndrome (PCOS). It provides supportive relief when symptoms interfere with routine activities.

“The primary goal is to help patients cope more steadily with symptom fluctuations associated with persistent facial hair growth.”

Description: Relief for Excessive Facial Hair (Hirsutism)

The treatment may assist with easing the appearance of hair over time, contributing to improved comfort by lessening the impact of frequent physical hair removal methods.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eflora (Eflornithine Hydrochloride cream) is strictly regulated for use within defined patient populations, as specified by official regulatory documents.

Eligibility Scope

Category	Regulatory Status
Populations for whom use is allowed	Women with unwanted facial hair (hirsutism) on the face and adjacent areas under the chin.
Populations for whom use is contraindicated	Patients with a known history of hypersensitivity to eflornithine or any component of the cream formulation.
Age-related eligibility rules	Approved for use in women 12 years of age and older (US/Canada). In Europe, it is indicated for women older than 18 years of age. Safety and effectiveness are not established in children younger than 12 years.

Condition-Specific Eligibility

Category	Eligibility Rule
Pregnancy and Lactation	Not recommended during pregnancy or while breastfeeding, as it is unknown if the substance is excreted in human milk and there are no well-controlled human studies.
Organ Function	Safety and efficacy have not been established in women with hepatic (liver) impairment. Caution should be used when prescribing to patients with severe renal (kidney) impairment due to lack of study data.

Connection to the Overall Eligibility Profile

The regulatory profile strictly defines eligibility by establishing absolute contraindications based on allergy and restrictions concerning age and sex. This structure ensures that use is only established in the labeled female population while advising against use when safety data is insufficient, such as during pregnancy or in cases of severe organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Topical Eflornithine Hydrochloride cream (Eflora) has a highly specific official interaction profile, primarily defined by its minimal systemic absorption. Regulatory agencies, including the FDA and the EMA, note that less than one percent of the applied dose reaches the bloodstream, severely limiting the potential for systemic drug-drug interactions.

Documented Interaction Profile

Interaction Type	Regulatory Status (Official Labeling)
Drug-Drug Interactions	None documented. Formal interaction studies have not been performed, and there are no known significant interactions with systemically administered medicines.
Metabolic/Transporter Interactions	None documented. Systemic exposure is too low to cause significant interactions via CYP enzymes or transport proteins.
Contraindicated Combinations	None based on drug-drug interaction risk.
Food, Alcohol, or Supplements	None documented. No known interactions with meals, alcohol, or herbal products are listed in official documents.

Application Constraints

While there are no documented drug-drug interaction restrictions, the official prescribing information includes a necessary timing constraint related to application procedures. Eflora must be applied at least five minutes after the unwanted hair has been removed by methods such as shaving or plucking. Furthermore, it is not known if Eflornithine interacts with other topically applied drug products, a limitation noted in the official prescribing information.

Mechanism of Action

Molecular Blockade of the ODC Enzyme

The mechanism begins with a highly specific molecular interaction where the active ingredient acts as an irreversible inhibitor of the Ornithine Decarboxylase (ODC) enzyme. This targeted process, known as "suicide inhibition," permanently deactivates the enzyme by forming a covalent bond at its active site, resulting in a molecular blockade that persists until the cell synthesizes new enzyme molecules.

Cytostatic Disruption and Physiological Consequence

The irreversible blockade of ODC halts the polyamine biosynthesis pathway, preventing the conversion of L-Ornithine to Putrescine and subsequently leading to a significant deficiency of essential polyamines (Spermidine, Spermine). Since polyamines are vital for cellular proliferation and differentiation, their depletion exerts a cytostatic (growth-slowing) effect specifically on the epithelial cells of the hair follicle with high turnover. The mechanistic consequence is a reduced rate of proliferation within the follicular structure, primarily affecting follicles in the Anagen (active growth) phase. Due to minimal systemic absorption, the effect is strongly localized and reversible; the proliferative rate returns to baseline once application ceases and ODC activity recovers.

Dosage and Administration Information

How to Use Eflora

Eflornithine Hydrochloride is formulated as a topical cream intended exclusively for application to the skin, specifically the face and adjacent involved areas under the chin. It is not designated for ophthalmic, oral, or internal use. The cream is typically available at a concentration of 13.9% or its equivalent in other regions.

Official Administration Pattern

Feature	General Guidelines
Route and Dosing	Apply a thin layer to the affected areas only.
Frequency	Twice daily, ensuring at least 8 hours separate each application.
Administration Sequence	Apply to clean, dry skin. Wait at least 5 minutes after hair removal before use. Cosmetics or sunscreens may be applied after the cream has absorbed (typically 5 minutes).
Washing Restriction	The treated area should not be washed for at least 4 hours following application.

Course Duration and Population Rules

Treatment duration is defined by specific guidelines for assessment. Improvement may be noticed within four to eight weeks of starting the regimen. Treatment is typically evaluated after a definitive period, such as four to six months, and is discontinued if no beneficial effects are observed. Continued and consistent application is necessary to sustain any observed effects.

Regarding specific patient groups, no dosage adjustment is considered necessary for older adults (65 years and over). Safety and efficacy have not been established in children under the age of 12 or under 18, depending on specific regional guidelines.

Recent Clinical Evidence

Research evidence / Overview of studies for Eflora

Evidence for the Reduction of Unwanted Facial Hair Growth

Research exploring Eflornithine cream has primarily used randomized, double-blind, vehicle-controlled trials (RCTs). This research design was used to compare the active cream against a neutral cream (the vehicle) without either the participant or the researcher knowing who received which. These studies focused on adult women with unwanted terminal facial hair, a condition known as hirsutism. The main outcomes research examined included Physician's Global Assessment (PGA) scores (a clinician's rating of hair parameters) and patient-reported outcomes (PROs) used in studies exploring patient-reported experiences.

The pivotal studies typically monitored participants over defined time intervals, usually up to 24 weeks (six months). Studies reported measurements showing that a greater number of participants using the active cream met pre-defined criteria for improvement on the PGA score compared to those using the vehicle cream over the 24-week period. Studies monitored outcomes linked to objective measures like hair density and hair mass measured during the study period.

Long-Term Studies and Durability of Findings

Research exploring short-term symptom changes focused on outcomes measured over the intermediate-term of 24 weeks. The data show patterns related to how symptoms evolved in the observed populations during this initial half-year period. However, long-term effects are not fully established beyond the one-year mark, as follow-up durations were limited in the pivotal trials.

Studies also explored what happens after treatment ceases. Research describes patterns indicating the measured changes in hair growth parameters appear to be reversible. Studies observed that after treatment cessation, hair growth parameters generally returned to measurements similar to those taken before the study within approximately eight weeks. This finding indicates that maintaining the measured outcomes was associated with continued application.

What Remains Uncertain in the Research Record

While research contributes to the broader evidence landscape, several limitations are noted. Long-term outcomes are not well characterized. Additionally, the evidence indicates that the cream was studied in a context where participants often continued using conventional hair removal methods throughout the trials. Evidence remains limited regarding the measured outcomes when the cream is used without any other concurrent hair removal practices over extended periods.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Eflora (FAQ)

Q: Is Eflora a steroid or hormone cream?

According to official product information, Eflornithine is classified as an Ornithine Decarboxylase (ODC) inhibitor. This means it works by targeting a specific enzyme in the hair follicle. It is considered a non-hormonal treatment and is not a steroid.

Q: Does Eflora work for hair removal on other parts of the body?

Regulatory documents state that Eflornithine cream is officially indicated only for the reduction of unwanted facial hair in women, specifically on the face and adjacent areas under the chin. The medication has only been studied and formally approved for use on these specific areas.

Q: How long can a person safely use Eflora cream?

Clinical studies primarily tracked a favorable safety profile during the first six months (24 weeks) of continuous use. Since continued application is generally necessary to maintain results, treatment may be ongoing. If no improvement is observed after six months, official guidelines suggest the treatment should be re-evaluated for discontinuation.

Q: Are there generic versions of Eflora?

The active ingredient in Eflora is Eflornithine Hydrochloride, which is the common generic name for this topical cream. Whether an FDA-approved generic product is available may depend on the specific market and product status.

Q: Does Eflora interact with common skin care products or makeup?

Official product guidelines note that cosmetics, makeup, or sunscreens may be applied over the treated area after the cream has dried and absorbed.

Q: Do I need a prescription from a dermatologist for Eflora?

The cream is a prescription-only medication. It must be prescribed by a licensed health care provider, though official documents do not specifically state that only a dermatologist must issue the prescription.

Q: Can Eflora make my skin more sensitive to the sun?

According to topical dermal studies, Eflornithine cream is generally not expected to cause phototoxic reactions. This means it is not known to increase skin sensitivity to the sun under normal conditions of use.

Q: Does Eflora cause weight gain?

Weight gain is not listed as a reported adverse event in the official drug labeling or safety profiles submitted to regulatory agencies.

Q: Can men use Eflora cream?

The medication is officially indicated for use only in women for the reduction of unwanted facial hair (hirsutism).

Q: Is Eflora a type of bleach or depilatory cream?

The cream is classified as an Ornithine Decarboxylase (ODC) Inhibitor, which is a targeted enzyme blocker that works to slow hair growth. It does not chemically remove hair and is not a bleach or a chemical depilatory product.

Q: Can Eflora be used with topical antibiotics or acne medication?

Official labeling notes that it is not known if Eflornithine cream interacts with other topically applied drug products, including topical antibiotics or acne medication. The official documents recommend consultation with a health care provider regarding co-administration of topical treatments, as interactions are not known.

Q: Has Eflora been studied in people with sensitive skin?

Clinical trials focused on adult women with unwanted facial hair. The official safety data commonly notes localized skin irritation as a potential adverse event, including stinging, burning, and redness.

Q: What should I do if I accidentally get Eflora in my eyes?

Official guidelines instruct users to avoid getting the cream into the eyes. The regulatory information advises rinsing the eyes well with water immediately and seeking guidance from a health care provider if accidental eye exposure occurs.

Q: What are the ingredients in Eflora besides the active component?

The official prescribing information lists the inactive ingredients, also called excipients, in the cream formulation. These components include various alcohols, parabens, and the cream base elements, such as mineral oil and water.

Q: Is Eflora considered a 'cure' for the condition it treats?

Eflornithine is not considered a cure because its effects are reversible. If use is stopped, studies indicate that the hair growth will generally return to the condition observed before treatment within about eight weeks.

Q: Why is Eflora only prescribed for facial use?

Regulatory approval restricts the use to the face and adjacent involved areas under the chin because the medication has only been studied and formally indicated for use in those areas. The product is designed to have a minimal and localized effect.

Q: If I miss a dose of Eflora, should I double the next one?

The official prescribing information states that extra cream should not be applied to make up for a missed dose.

Q: Can Eflora be used in conjunction with electrolysis?

The official labeling states that the medication can be used as an adjunct to conventional hair removal methods.

Q: Can Eflora be used on sunburned skin?

Official safety information notes that transient stinging or burning may occur when the cream is applied to irritated or abraded (broken) skin. The official product labeling directs that the cream should be applied only to intact skin.

Q: Does Eflora have any systemic effects on the body?

Studies show that systemic exposure to the drug is minimal, with less than 1% of the applied dose being absorbed into the bloodstream. Due to this low level of absorption, serious systemic side effects from topical overdose are not expected.

Q: What happens if I forget to wash my hands after applying Eflora?

Official guidelines state that hands should be washed both before and after application of the cream.

How should Eflora be stored and disposed of?

How to Store and Dispose of Eflornithine Hydrochloride Cream

Official regulatory guidelines strictly define the necessary storage and disposal requirements for Eflornithine cream.

Storage Conditions

The cream must be stored at room temperature, specifically below 30 C (86 F), and must not be frozen. The product should be kept in its original container with the cap tightly closed and away from excess heat and moisture. A critical safety requirement is to keep this medication out of the sight and reach of children.

Stability and Disposal

Once the tube is opened, any remaining cream must be discarded after 6 months to ensure product stability. When disposing of unused or expired cream, it must not be flushed down the toilet or thrown into household waste. Instead, dispose of the product through a medicine take-back program or as directed by local regulations to protect the environment.

Eflora